Allan Camaisa Sells 10,000 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) Stock

Calidi Biotherapeutics, Inc. (NYSE:CLDI) CEO Allan Camaisa sold 10,000 shares of Calidi Biotherapeutics stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $1.62, for a total transaction of $16,200.00. Following the transaction, the chief executive officer now directly owns 66,712 shares in the company, valued at approximately $108,073.44. This represents a 13.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Calidi Biotherapeutics Trading Up 0.7 %

Shares of NYSE:CLDI opened at $1.45 on Friday. Calidi Biotherapeutics, Inc. has a 12 month low of $0.73 and a 12 month high of $18.50. The stock’s fifty day moving average is $1.69.

Calidi Biotherapeutics (NYSE:CLDI) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.20. Research analysts predict that Calidi Biotherapeutics, Inc. will post -4.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Calidi Biotherapeutics

A hedge fund recently raised its stake in Calidi Biotherapeutics stock. Delta Investment Management LLC increased its position in shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) by 1,955.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 210,230 shares of the company’s stock after purchasing an additional 200,000 shares during the quarter. Delta Investment Management LLC owned approximately 0.41% of Calidi Biotherapeutics worth $42,000 as of its most recent SEC filing. 12.53% of the stock is currently owned by institutional investors and hedge funds.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.